Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:DSGN NASDAQ:MDWD NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.05-1.5%$6.97$4.73▼$9.53$740.25M0.4548,136 shs439,329 shsDSGNDesign Therapeutics$11.87-0.1%$12.39$3.76▼$17.25$741.99M1.58703,319 shs489,104 shsMDWDMediWound$14.62+1.2%$14.63$13.54▼$20.62$185.71M0.1470,318 shs46,085 shsMNPRMonopar Therapeutics$109.09-1.1%$82.66$29.18▼$116.64$739.11M1.46227,753 shs528,969 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-1.54%+0.28%+0.71%+4.75%+0.86%DSGNDesign Therapeutics-0.08%-1.58%-11.09%-24.83%+193.81%MDWDMediWound+1.18%+2.38%-3.75%-10.03%-26.64%MNPRMonopar Therapeutics-1.12%-3.94%+24.42%+117.66%+151.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$7.05-1.5%$6.97$4.73▼$9.53$740.25M0.4548,136 shs439,329 shsDSGNDesign Therapeutics$11.87-0.1%$12.39$3.76▼$17.25$741.99M1.58703,319 shs489,104 shsMDWDMediWound$14.62+1.2%$14.63$13.54▼$20.62$185.71M0.1470,318 shs46,085 shsMNPRMonopar Therapeutics$109.09-1.1%$82.66$29.18▼$116.64$739.11M1.46227,753 shs528,969 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences-1.54%+0.28%+0.71%+4.75%+0.86%DSGNDesign Therapeutics-0.08%-1.58%-11.09%-24.83%+193.81%MDWDMediWound+1.18%+2.38%-3.75%-10.03%-26.64%MNPRMonopar Therapeutics-1.12%-3.94%+24.42%+117.66%+151.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.25Hold$20.50190.78% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5039.01% UpsideMDWDMediWound 2.25Hold$34.00132.56% UpsideMNPRMonopar Therapeutics 3.07Buy$112.082.74% UpsideCurrent Analyst Ratings BreakdownLatest MDWD, DSGN, AURA, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$125.007/22/2026MNPRMonopar Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$105.00 ➝ $125.007/17/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026MDWDMediWound Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026MNPRMonopar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/15/2026MNPRMonopar Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/14/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/13/2026MNPRMonopar Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/30/2026MNPRMonopar Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$104.00 ➝ $117.006/29/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/29/2026MNPRMonopar Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.00(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AMDWDMediWound$14.48M12.98N/AN/A$3.40 per share4.30MNPRMonopar TherapeuticsN/AN/AN/AN/A$20.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.74N/AN/AN/AN/A-78.12%-64.08%8/12/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)MDWDMediWound-$23.88M-$2.26N/AN/AN/A-180.30%-67.22%-31.87%8/13/2026 (Estimated)MNPRMonopar Therapeutics-$13.72M-$1.90N/AN/AN/AN/A-12.84%-12.57%8/11/2026 (Estimated)Latest MDWD, DSGN, AURA, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MDWDMediWound-$0.76N/AN/AN/A$2.59 millionN/A8/12/2026Q2 2026AURAAura Biosciences-$0.41N/AN/AN/AN/AN/A8/11/2026Q2 2026MNPRMonopar Therapeutics-$0.67N/AN/AN/AN/AN/A8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A5/27/2026Q1 2026MDWDMediWound-$0.65-$0.23+$0.42-$0.23$3.37 million$1.48 million5/21/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/A5/14/2026Q1 2026MNPRMonopar Therapeutics-$0.8703-$0.46+$0.4103-$0.46N/AN/A5/11/2026Q1 2026AURAAura Biosciences-$0.40-$0.50-$0.10-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A7.097.09DSGNDesign TherapeuticsN/A22.2822.28MDWDMediWoundN/A2.412.19MNPRMonopar TherapeuticsN/A56.0456.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%DSGNDesign Therapeutics56.64%MDWDMediWound46.83%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences1.90%DSGNDesign Therapeutics17.10%MDWDMediWound9.20%MNPRMonopar Therapeutics9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences50103.39 million101.42 millionNot OptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableMDWDMediWound8012.85 million11.67 millionOptionableMNPRMonopar Therapeutics106.70 million6.05 millionNot OptionableMDWD, DSGN, AURA, and MNPR HeadlinesRecent News About These CompaniesMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Rating of "Buy" by AnalystsJuly 28 at 2:14 AM | americanbankingnews.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Recommendation of "Buy" from AnalystsJuly 28 at 2:13 AM | marketbeat.comEquities Analysts Offer Predictions for MNPR FY2027 EarningsJuly 26 at 1:28 AM | americanbankingnews.comHC Wainwright Has Positive Outlook of MNPR FY2027 EarningsJuly 24, 2026 | marketbeat.comSiren L.L.C. Increases Stake in Monopar Therapeutics Inc. $MNPRJuly 24, 2026 | marketbeat.comWalleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPRJuly 24, 2026 | marketbeat.comHC Wainwright Increases Monopar Therapeutics (NASDAQ:MNPR) Price Target to $125.00July 24, 2026 | americanbankingnews.comMonopar Therapeutics (NASDAQ:MNPR) Stock Price Down 8.9% - What's Next?July 23, 2026 | marketbeat.comHC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock PriceJuly 22, 2026 | marketbeat.comMonopar Initiates Rolling NDA Submission for ALXN1840 in Wilson DiseaseJuly 22, 2026 | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 12-Month High - What's Next?July 20, 2026 | marketbeat.comMonopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership TeamJuly 20, 2026 | globenewswire.comMonopar: A Rare Disease Asset With Heavy-Metal Upside (Initiating Buy)July 17, 2026 | seekingalpha.comMonopar Therapeutics (NASDAQ:MNPR) Shares Up 6.8% - What's Next?July 15, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Upgraded at Zacks ResearchJuly 15, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Lowered to "Sell" Rating by Wall Street ZenJuly 12, 2026 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Hits New 12-Month High - Here's WhyJuly 9, 2026 | marketbeat.comMonopar Therapeutics: ALXN1840's Bull Case Has ImprovedJuly 3, 2026 | seekingalpha.comMonopar Wins FDA Rare Pediatric Disease DesignationJuly 1, 2026 | theglobeandmail.comMonopar Therapeutics Inc (MNPR) Gets a Buy from Lake StreetJuly 1, 2026 | theglobeandmail.comMonopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson DiseaseJune 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesGold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?By Nathan Reiff | June 29, 2026New Stock Price Highs Are on the Menu for Darden RestaurantsBy Thomas Hughes | June 29, 2026Confidence Is Back, But Earnings Show the Consumer Is Being PickyBy Jessica Mitacek | July 21, 2026Burger King’s Turnaround Is Putting Restaurant Brands Back in FocusBy Peter Frank | July 1, 2026Toast’s Comeback Story Is Getting Harder for Wall Street to IgnoreBy Chris Markoch | July 16, 2026MDWD, DSGN, AURA, and MNPR Company DescriptionsAura Biosciences NASDAQ:AURA$7.05 -0.11 (-1.54%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$7.05 0.00 (0.00%) As of 07/28/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Design Therapeutics NASDAQ:DSGN$11.87 -0.01 (-0.08%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$11.86 0.00 (-0.04%) As of 07/28/2026 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.MediWound NASDAQ:MDWD$14.62 +0.17 (+1.18%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$14.54 -0.08 (-0.58%) As of 07/28/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Monopar Therapeutics NASDAQ:MNPR$109.09 -1.24 (-1.12%) Closing price 07/28/2026 04:00 PM EasternExtended Trading$109.04 -0.05 (-0.04%) As of 07/28/2026 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Stocks Have Soared in 2026—Can They Keep Climbing? Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
